Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .
Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1.
Few well-controlled diet studies have investigated the effects of reducing dietary saturated fatty acid ( SFA ) intake in premenopausal and postmenopausal women or in blacks . We conducted a multicenter , r and omized , crossover- design trial of the effects of reducing dietary SFA on plasma lipids and lipoproteins in 103 healthy adults 22 to 67 years old . There were 46 men and 57 women , of whom 26 were black , 18 were postmenopausal women , and 16 were men > or = 40 years old . All meals and snacks , except Saturday dinner , were prepared and served by the research centers . The study was design ed to compare three diets : an average American diet ( AAD ) , a Step 1 diet , and a low-SFA ( Low-Sat ) diet . Dietary cholesterol was constant . Diet composition was vali date d and monitored by a central laboratory . Each diet was consumed for 8 weeks , and blood sample s were obtained during weeks 5 through 8 . The compositions of the three diets were as follows : AAD , 34.3 % kcal fat and 15.0 % kcal SFA ; Step 1 , 28.6 % kcal fat and 9.0 % kcal SFA ; and Low-Sat , 25.3 % kcal fat and 6.1 % kcal SFA . Each diet provided approximately 275 mg cholesterol/d . Compared with AAD , plasma total cholesterol in the whole group fell 5 % on Step 1 and 9 % on Low-Sat . LDL cholesterol was 7 % lower on Step 1 and 11 % lower on Low-Sat than on the AAD ( both P<.01 ) . Similar responses were seen in each subgroup . HDL cholesterol fell 7 % on Step 1 and 11 % on Low-Sat ( both P<.01 ) . Reductions in HDL cholesterol were seen in all subgroups except blacks and older men .  Plasma triglyceride levels increased approximately 9 % between AAD and Step 1 but did not increase further from Step 1 to Low-Sat . Changes in triglyceride levels were not significant in most subgroups . Surprisingly , plasma Lp(a ) concentrations increased in a stepwise fashion as SFA was reduced . In a well-controlled feeding study , stepwise reductions in SFA result ed in parallel reductions in plasma total and LDL cholesterol levels . Diet effects were remarkably similar in several subgroups of men and women and in blacks . The reductions in total and LDL cholesterol achieved in these different subgroups indicate that diet can have a significant impact on risk for atherosclerotic cardiovascular disease in the total population
Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .